<?xml version="1.0" encoding="UTF-8"?>
<ref id="B92-biomedicines-08-00109">
 <label>92.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Omrani</surname>
    <given-names>A.S.</given-names>
   </name>
   <name>
    <surname>Saad</surname>
    <given-names>M.M.</given-names>
   </name>
   <name>
    <surname>Baig</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Bahloul</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Abdul-Matin</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Alaidaroos</surname>
    <given-names>A.Y.</given-names>
   </name>
   <name>
    <surname>Almakhlafi</surname>
    <given-names>G.A.</given-names>
   </name>
   <name>
    <surname>Albarrak</surname>
    <given-names>M.M.</given-names>
   </name>
   <name>
    <surname>Memish</surname>
    <given-names>Z.A.</given-names>
   </name>
   <name>
    <surname>Albarrak</surname>
    <given-names>A.M.</given-names>
   </name>
  </person-group>
  <article-title>Ribavirin and interferon alpha-2a for severe Middle East respiratory syndrome coronavirus infection: A retrospective cohort study</article-title>
  <source>Lancet Infect. Dis.</source>
  <year>2014</year>
  <volume>14</volume>
  <fpage>1090</fpage>
  <lpage>1095</lpage>
  <pub-id pub-id-type="doi">10.1016/S1473-3099(14)70920-X</pub-id>
  <pub-id pub-id-type="pmid">25278221</pub-id>
 </element-citation>
</ref>
